2016 ACR/ARHP Annual Meeting

November 11-16, 2016. Washington, DC.

View by Number View by Title View Sessions

View by Date

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

Abstract Number: 895

Incidence of Osteoporotic Mayor Fractures in a Cohort of Patients with Polymyalgia Rheumatica
Abstract Number: 1167

Incidence of Primary Chronic Cutaneous Lupus Erythematosus in a Metropolitan Area of the Southeastern United States: The Georgia Lupus Registry
Abstract Number: 1312

Incidence of Reactive Arthritis, Uveitis and Conjunctivitis in Japanese Patients with Bladder Cancer Following Intravesical BCG Therapy: A 20 Years’ Two-Center Retrospective Study
Abstract Number: 1489

Incident Hypertension and Associated Factors in a Hispanic Group with Rheumatoid Arthritis
Abstract Number: 319

Incident Participation Restriction in Adults with Knee Osteoarthritis: Do Positive and Negative Affect Matter? the Multicenter Osteoarthritis Study
Abstract Number: 2298

Incident Risk of Acute Gout Among Active Smokers: Data from Nationwide Inpatient Sample
Abstract Number: 690

Increase in Serum Leptin Levels Is Associated with Radiographic Progression of Male Patients with Ankylosing Spondylitis: A 2-Year Longitudinal Study
Abstract Number: 1409

Increase in the Use of Validated Disease Activity Scores in Current Daily Clinical Practice Compared to 2007
Abstract Number: 2975

Increase of Sacroiliitis By Follow-up and Routine CT in Patients with Behcet’s Disease
Abstract Number: 1569

Increased Circulating CD14brightCD16+ Intermediate Monocytes Are Regulated By Interleukin-10 in Patients with Rheumatoid Arthritis
Abstract Number: 926

Increased Concentration of Receptor Activator of Nuclear Factor Kappa-B Ligand (RANKL) Predate Onset of Rheumatoid Arthritis
Abstract Number: 1895

Increased CXCL4/PF4 Presence in Systemic Sclerosis and Absence of Heparin Directed Autoantibodies
Abstract Number: 1077

Increased Expression of B-Cell Lipid Rafts in Patients with Primary Sjogren’s Syndrome Correlated Positively with Disease Activity Score, Suggesting a B Cell Activated State Potentially Relevant for the Disease Pathogenesis and Response to Biologic Therapies
Abstract Number: 2062

Increased Expression of Response Gene to Complement-32 in Kidney Biopsies from Patients with Lupus Nephritis
Abstract Number: 280

Increased Expression of TIF-1 Gamma in Duodenal Adenocarcinoma from a Patient with p155/140 Dermatomyositis: A Causal Relationship?

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].